By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelrys reported after the close of the market on Monday a 70 percent jump year over year in second-quarter revenues.

For the three months ended June 30, the San Diego-based firm posted $33.7 million in revenues, up from $19.8 million a year ago. The increase was led by license and subscription revenues, which climbed to $18.6 million, a 21 percent increase, while maintenance on perpetual licenses jumped 258 percent to $8.6 million from $2.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.